

WORLD ALZHEIMER'S DAY

Grifols strengthens evidence supporting the AMBAR[®] program in Alzheimer's disease with real-world evidence data

- *On the occasion of World Alzheimer's Day, Grifols announces that new real-world evidence (RWE) data expanding the evidence base of the AMBAR[®] (Alzheimer Management by Albumin Replacement) study will be presented at the Annual Meeting of the Spanish Society of Neurology (SEN), taking place in Seville this November*

Barcelona, Spain, September 19, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, is strengthening the evidence supporting the AMBAR[®] (Alzheimer Management by Albumin Replacement) program with new real-world evidence (RWE) data that broaden understanding of the applicability of therapeutic plasma exchange with albumin replacement in patients with Alzheimer's disease.

The AMBAR study has shown a 61% reduction in disease progression in patients with mild to moderate Alzheimer's disease compared with untreated patients.¹

Grifols and Ace Alzheimer Center Barcelona jointly develop the program through the AMBAR Center in Barcelona. In addition, the AMBAR protocol has begun to be implemented at HM Sanchinarro University Hospital in Madrid and Juaneda Clinic in Palma de Mallorca. The company is also in discussions with other hospitals across Spain to explore the progressive adoption of the protocol at additional centers.

At the Annual Meeting of the Spanish Society of Neurology (SEN), taking place in Seville from November 17 to 21, new real-world evidence data from the AMBAR program will be presented. The findings expand the available evidence regarding the applicability of therapeutic plasma exchange with albumin replacement under routine clinical practice conditions.

"Real-world evidence is a valuable complement to data obtained from clinical trials and helps broaden our understanding of this therapeutic approach and its implementation in patients with Alzheimer's disease," said Dr. Mercè Boada, founder and Senior Medical Advisor of Ace Alzheimer Center Barcelona.

"Data generated in routine clinical practice are essential to continue expanding our understanding of Alzheimer's disease and the potential of different therapeutic approaches," said Dr. Antonio Páez, VP, Neuro Innovation Hub at Grifols. "These findings contribute to expanding scientific knowledge of the disease and to continuing the exploration of new options that may improve the care and quality of life of people living with Alzheimer's disease and their families."

¹ Boada M, López OL, Olazarán J et al. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. *Alzheimers Dement*. 2020 Oct;16(10):1412-1425. doi: [10.1002/alz.12137](https://doi.org/10.1002/alz.12137).

Memory Week: Promoting early detection

Coinciding with World Alzheimer's Day on September 21, Grifols is collaborating with the AMBAR Clinics in Madrid and Mallorca to organize a 'Memory Week', an initiative aimed at raising public awareness about the importance of recognizing potential cognitive changes at their earliest stages.

The initiative will take place at HM Sanchinarro University Hospital and HM Madrid University Hospital in Madrid, as well as at Juaneda Clinic in Palma de Mallorca.

Through scientific research and awareness initiatives such as the 'Memory Week', Grifols reaffirms its commitment to advancing knowledge of Alzheimer's disease and improving care for people living with the condition.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com.

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Phone: +34 93 571 00 02

INVESTORS:

Investor Relations & Sustainability

investors@grifols.com – inversores@grifols.com

sustainability@grifols.com – sostenibilidad@grifols.com

Phone: +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.